Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Fosun
Fosun
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Fosun Pharma invests $50m in BioNTech for its COVID-19 vaccine
The two companies have agreed to develop BNT162 in China leveraging Fosun’s capabilities in the country
Finance
Chinese facility changes hands from GSK to Fosun Pharmaceutical
The deal has been reported to be worth US$36 million
Finance
ReNeuron and Fosun Pharma join forces in China
For exclusive rights to its CTX and hRPC cell therapy programmes, ReNeuron will receive £6 million upfront, and approximately £80 million in milestone payments
Regulatory
Sirona Biochem announces SGLT2 IND submission
Sirona Biochem announced its partner Wanbang Biopharmaceuticals has confirmed an investigational new drug (IND) submission to China's Food and Drug Administration (CFDA) for its SGLT2 inhibitor
Subscribe now